Why Is Tempus AI (TEM) Stock Up +10.46% Today?
Key Takeaways
- TEM shares jumped roughly 10.46% on September 17, 2026, climbing from a prior close of $69.97 to about $77.29.
- The primary catalyst was an analyst upgrade from Piper Sandler, which lifted TEM to Overweight and raised its price target from $56 to $76.
- Supportive drivers included a $9.5 million federal grant tied to cardiology AI development and renewed enthusiasm around its pending acquisition of PSNL (Personalis).
- The move tracked a broad rally in AI and healthcare-technology names, adding momentum to the stock's multi-week advance.
- Traders are watching integration milestones for the Personalis deal, oncology-testing adoption, and the company's next earnings report.
Opening Summary
TEM, the ticker for Tempus AI, Inc., is a healthcare-technology company that applies artificial intelligence and machine learning to precision medicine, combining molecular testing with clinical data to help physicians make more informed treatment decisions. On September 17, 2026, the stock surged approximately 10.46%, rising from a prior session close of $69.97 to around $77.29 in intraday trading. The move, confirmed as a significant gain, was driven primarily by an analyst upgrade alongside positive sector sentiment and company-specific developments in oncology diagnostics and cardiology AI.
Analyst Upgrade
The clearest catalyst behind the rally was an upgrade from Piper Sandler, which moved its rating on TEM from Neutral to Overweight and raised its price target to $76 from $56. The analyst cited three emerging growth drivers: the pending acquisition of PSNL (Personalis), favorable results from the INTerpath-001 study, and FDA clearance of the xT CDx test. The shift in stance signaled that the firm now sees tangible fundamental progress supporting the valuation, rather than enthusiasm for artificial intelligence alone, prompting investors to reprice the stock higher.
Personalis Acquisition and Oncology Momentum
The planned acquisition of PSNL (Personalis) remained a central focus. The transaction gives Tempus access to a tumor-informed minimal residual disease (MRD) platform, a capability analysts view as a distinctive asset in oncology diagnostics. Favorable results from the INTerpath-001 study strengthened the strategic case for the deal, while the FDA's clearance of the tumor-only xT CDx test removed a key regulatory hurdle and supported the company's path toward unified ADLT pricing across its diagnostic portfolio. The combination of these milestones reinforced confidence in TEM's longer-term growth trajectory.
Federal Grant and Broader AI Sentiment
Additional support came from news that the company secured a roughly $9.5 million federal grant tied to cardiology AI development, underscoring the expanding application of its platform beyond oncology. The stock also benefited from a wider rally in AI-related equities, with healthcare-AI names trading higher alongside strength in the technology sector. This favorable backdrop amplified the move, as investors rotated toward companies perceived to be translating AI investments into commercial traction.
Market Context and Trading Activity
Trading volume in TEM was elevated relative to its average, reflecting heightened investor interest following the upgrade and related announcements. The advance extended a multi-week uptrend that had already carried the shares well above their 50-day and 200-day moving averages. The gain outpaced the broader market, indicating that company-specific catalysts, rather than a simple index move, drove the outperformance even as the broader AI and healthcare-technology complex traded firmly.
What Comes Next for TEM
Looking ahead, investors will monitor progress on closing the Personalis acquisition, which is expected to complete in late 2026 or early 2027, as well as the integration of its MRD capabilities. Continued adoption of the company's oncology diagnostics and data-licensing businesses, along with execution on recent federal funding, will be closely watched. The company's next earnings report is scheduled for early November, offering the next major checkpoint on revenue growth and profitability. Risks include the company's history of net losses, insider selling, and the high volatility typical of AI-focused healthcare names.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Only the top performers are featured in this section. Explore the Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TEM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on TEM as a result. In 30 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +9.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 110 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 48 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 21 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (34.722) is very high in comparison to the industry average of (7.432). P/E Ratio (39.298) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement